Type of information: Series C financing round
Company: Omeicos Therapeutics (Germany)
Investors: Forbion Capital Partners (The Netherlands) Vesalius Biocapital (Luxembourg) SICAR (Luxembourg) VC Fonds Technologie Berlin (Germany) Hightech Gruenderfonds II GmbH & Co. KG (HTGF) (Germany) KfW Group (Germany) The Falck Revocable Trust, members of the management
Amount: € 17 million
Funding type: series C financing round
- The proceeds from this series C financing round will finance PROMISE-AF, a placebo controlled, double-blinded, randomized, dose finding Phase II study on OMT-28 in maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation.
- The company's compounds are synthetic analogs of naturally occurring, but metabolically unstable, metabolites of omega-3 fatty acids that can activate anti-arrhythmic, cardio protective and anti-inflammatory pathways. These small molecules can be administered orally and have shown improved biological activity and pharmacokinetic properties compared to their natural counterparts.
- Additionally, Omeicos will continue to drive the expansion of its pipeline into novel indications including ophthalmology, led by its US-based subsidiary Omeicos Ophthalmics. These compounds are currently in preclinical development for macular edema disease, including wet age-related macular degeneration (AMD) and diabetic retinopathy.
- • On November 2, 2018, OmeicosTherapeutics announced the closing of a € 17 million (approx. USD 19.5 million) Series C financing led by new investor Forbion. Existing investors Vesalius Biocapital II S.A. SICAR, Remiges BioPharma Fund, SMS Group GmbH, KFW Group, VC Fonds Technologie Berlin, High-Tech Gründerfonds II GmbH & Co. KG and The Falck Revocable Trust participated as well.
Therapeutic area: Cardiovascular diseases - Ophtalmological diseases